Biocon, NCSM partner to launch oncology support program

This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia.

The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.

Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, “Our partnership with the National Cancer Society of Malaysia marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. This collaboration, which combines our scientific expertise with NCSM’s strong community outreach and patient support network, aims to ease the treatment burden for underserved populations. Together, we hope to positively impact thousands of lives and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.”

"Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this," the company stated in its recent release.